
Overview
Life sciences tech firm's preliminary Q4 revenue up 37%, slightly beating analyst expectations
Company received record order from top biopharma client for global manufacturing automation
Preliminary full-year 2025 revenue grew 20%
Outlook
Rapid Micro Biosystems expects full-year 2025 revenue of approximately $33.6 mln
Company anticipates continued growth in 2026 supported by strategic partnerships
Result Drivers
RECORD ORDER - Co received record multi-system order from a top biopharma client for global manufacturing automation
SYSTEM PLACEMENTS - Placement of 16 new Growth Direct systems in Q4 contributed to revenue growth
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Slight Beat* | $11.30 mln | $11.20 mln (4 Analysts) |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Rapid Micro Biosystems Inc is $8.00, about 160.6% above its January 12 closing price of $3.07
Press Release: ID:nGNX6KPRbP
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.